Antiemetic for intravenous infusion

Product Description:

Adults

• Prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy (CINV/RINV)
• Prevention and treatment of post-operative nausea and vomiting (PONV).

Paediatric population

• Management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥ 6 months
• Prevention and treatment of postoperative nausea and vomiting (PONV) in children aged ≥ 1 month.

Available in:

• Ondansetron 0.08 mg/ml: Ecoflac® plus 100 ml
• Ondansetron 0.16 mg/ml: Ecoflac® plus 50 ml

Advantages:

• MHRA advice for healthcare professionals to dilute Ondansetron and infuse over at least 15 minutes for patients age 65 years or older.
• Ready-to-use dose product eliminates intermediate steps and helps to prevent dosage errors.